164 related articles for article (PubMed ID: 27173161)
1. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
[TBL] [Abstract][Full Text] [Related]
2. 89Zr-bevacizumab PET imaging in primary breast cancer.
Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
[TBL] [Abstract][Full Text] [Related]
3. Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
van Asselt SJ; Oosting SF; Brouwers AH; Bongaerts AH; de Jong JR; Lub-de Hooge MN; Oude Munnink TH; Fiebrich HB; Sluiter WJ; Links TP; Walenkamp AM; de Vries EG
J Nucl Med; 2014 Jul; 55(7):1087-92. PubMed ID: 24790218
[TBL] [Abstract][Full Text] [Related]
4.
van Es SC; Brouwers AH; Mahesh SVK; Leliveld-Kors AM; de Jong IJ; Lub-de Hooge MN; de Vries EGE; Gietema JA; Oosting SF
J Nucl Med; 2017 Jun; 58(6):905-910. PubMed ID: 28082434
[TBL] [Abstract][Full Text] [Related]
5. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Oosting SF; Brouwers AH; van Es SC; Nagengast WB; Oude Munnink TH; Lub-de Hooge MN; Hollema H; de Jong JR; de Jong IJ; de Haas S; Scherer SJ; Sluiter WJ; Dierckx RA; Bongaerts AH; Gietema JA; de Vries EG
J Nucl Med; 2015 Jan; 56(1):63-9. PubMed ID: 25476536
[TBL] [Abstract][Full Text] [Related]
6. Molecular Drug Imaging:
Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E
J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849
[TBL] [Abstract][Full Text] [Related]
8. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
[TBL] [Abstract][Full Text] [Related]
9. The utility of
Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E
Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201
[TBL] [Abstract][Full Text] [Related]
10. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
11. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
12. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
[TBL] [Abstract][Full Text] [Related]
13. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau Disease-Associated Retinal Hemangioblastoma.
Papadakis GZ; Millo C; Jassel IS; Bagci U; Sadowski SM; Karantanas AH; Patronas NJ
Clin Nucl Med; 2017 Mar; 42(3):189-190. PubMed ID: 28033220
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
17. Kidney Tumor in a von Hippel-Lindau (VHL) Patient With Intensely Increased Activity on 68Ga-DOTA-TATE PET/CT.
Papadakis GZ; Millo C; Sadowski SM; Bagci U; Patronas NJ
Clin Nucl Med; 2016 Dec; 41(12):970-971. PubMed ID: 27749408
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography.
Golestani R; Zeebregts CJ; Terwisscha van Scheltinga AG; Lub-de Hooge MN; van Dam GM; Glaudemans AW; Dierckx RA; Tio RA; Suurmeijer AJ; Boersma HH; Nagengast WB; Slart RH
Mol Imaging; 2013 Jun; 12(4):235-43. PubMed ID: 23651501
[TBL] [Abstract][Full Text] [Related]
19. Potential value of EUS in pancreatic surveillance of VHL patients.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Koopmans KP; Kema IP; Zonnenberg BA; Timmers HJ; de Herder WW; Sluiter WJ; de Vries EG; Links TP
Eur J Endocrinol; 2016 May; 174(5):611-20. PubMed ID: 26884551
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease.
Ambrosini V; Campana D; Allegri V; Opocher G; Fanti S
Clin Nucl Med; 2011 Jan; 36(1):64-5. PubMed ID: 21157217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
